Login to Your Account



Tandem Tipping Point

Xalkori and Zelboraf Prove Efficiency of RxDx Strategy

By Trista Morrison


Tuesday, September 6, 2011
For years, the drug industry has known its cost of developing a new product – estimated at $1.3 billion – is not sustainable. For years, companion diagnostics have been considered as a potential solution to that problem. And for years, the result has been a lot of talk, but very little action.

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription